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Summary
This article summarizes recommendations reached following a systematic litera-
ture review and expert consensus on the diagnosis and management of cutaneous
squamous cell carcinomas in people with epidermolysis bullosa. The guidelines
are intended to help inform decision making by clinicians dealing with this com-
plex complication of a devastating disease.
What’s already known about this topic?
• Some subtypes of epidermolysis bullosa (EB), particularly severe generalized reces-
sive dystrophic EB, are associated with the development of mucocutaneous squa-
mous cell carcinomas (SCCs).
• These tumours behave aggressively and are a leading cause of morbidity and mor-
tality in at-risk patients with EB.
What does this study add?
• These guidelines will assist clinicians in the diagnosis, management and staging of
EB-associated cutaneous SCCs based on available evidence and expert consensus.
• They highlight the importance of a holistic multidisciplinary approach to the management
of EB-associated SCCs, where patient involvement in decision making is paramount.
© 2015 The Authors. British Journal of Dermatology
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Some forms of epidermolysis bullosa (EB) are associated with
the development of cutaneous or, more rarely, mucosal squa-
mous cell carcinoma (SCC). Unlike cutaneous SCCs occurring
in the general population where chronic ultraviolet exposure
predisposes to the development of tumours on sun-exposed
sites, EB-associated SCCs tend to arise at sites of chronic skin
blistering, wounds and scarring. In addition, multiple primary
SCCs often occur, tumours generally behave more aggressively
than conventional SCCs, and they carry a very significant mor-
bidity and mortality for those affected. EB cancers are the lead-
ing cause of death in patients with recessive dystrophic EB
(RDEB), particularly the severe generalized form (RDEB-SG).
The cumulative risk of developing SCC in EB increases with
age: for patients with RDEB-SG, the cumulative risk of having
at least one SCC is 75% at age 20 years, 678% at 35 years
and 901% by 55 years.1 This increased risk is paralleled by
an increased cumulative risk of death from SCC in this type of
EB: 387% by age 35 years, 700% by 45 years and 787% by
55 years. These deaths occur despite aggressive tumour resec-
tion. The risks for patients with other forms of EB prone to
SCC are lower, with tumours occurring later in life and tend-
ing to be less aggressive. It is also important to acknowledge
that many EB subtypes, especially EB simplex, are not associ-
ated with an increased SCC risk.1
Clinical detection of SCCs in patients with EB on a back-
ground of chronic ulceration may be particularly challenging,
and therefore the possibility of malignancy should be borne in
mind, with suspicious lesions biopsied for histological evalua-
tion. Hitherto, there have been many case reports in the litera-
ture describing EB SCCs and a variety of approaches towards
investigation, monitoring and treatment. However, given the
rarity of EB and the occurrence of cancer in a subset of
patients only, there has been no prospective work or trials
looking at how these tumours should best be managed.
DEBRA International is a worldwide network of national
groups working on behalf of those affected by EB. In order to
improve the diagnosis and management of SCCs arising in
people with EB, they commissioned these guidelines, which
have been drawn up from a systematic review of the available
literature and guided by expert consensus. They are divided
into sections on monitoring and surveillance for EB cancers,
diagnosis, and surgical and nonsurgical treatments. Sections on
putative preventative measures and palliative care have also
been included.
Aim
To provide the user with information on the diagnosis and
management of SCCs in people with EB so as to improve
patient outcomes and quality of life.
Users
Dermatologists, paediatricians, plastic surgeons, dermatological
surgeons, oncologists, dermatopathologists, palliative care
physicians, nurses and people living with EB.
Target group
This guideline is aimed at adolescent and adult patients with
forms of EB associated with the development of mucocuta-
neous SCCs, notably those with RDEB, dominant dystrophic
EB, generalized intermediate junctional EB and Kindler
syndrome.
Methods
In 2010, an international multidisciplinary working group
was established to undertake a systematic review of the litera-
ture pertaining to the development, investigation and man-
agement of SCCs in people with EB, and to develop clinical
recommendations based on the literature and their own
expert opinions. This group included the following spe-
cialties: dermatology, plastic surgery, medical oncology, sur-
gical oncology, dermatopathology, specialist nursing and
palliative care.
The systematic literature searches were conducted using
Medline, CINAHL, Allied and Complimentary Medicine Data-
base, British Nursing Index, Embase and PsychINFO using the
search terms ‘epidermolysis bullosa’, ‘cancer’ and ‘squamous
cell carcinoma’. The search was limited to articles about
humans in English or French with no other restrictions. The
literature review was updated in April 2014 with new publica-
tions incorporated into the review.
Topics for the guidelines, which had been determined by
the group prior to the systematic review, were used to for-
mulate initial recommendations that then formed the basis
for subsequent iterations based on review and consensus by
the expert collaborators. Importantly, particular regard was
made in ensuring that the guidelines were clinically relevant
and applicable to practice throughout the world, where the
availability of various diagnostic and therapeutic modalities
may be limited. The draft guidelines were then circulated for
comments from people with EB, their families and a lay
person.
In order to formulate the recommendations from the
selected studies, the Scottish Intercollegiate Guidelines Network
guidelines were used (Appendix 1). These detail the strength
of recommendations and quality of evidence used herein.
Search results
In total 376 papers or conference abstracts meeting the search
criteria were identified. Of these, 300 were discarded as they
were not relevant (e.g. they did not pertain to inherited forms
of EB), they comprised duplicate material or did not contain
information concerning screening, diagnosis or management
of EB-associated SCCs. Most articles were single case reports
or small series of patients with EB with cutaneous SCCs, with
no clinical trials identified in this group of patients. Additional
references relating to other aspects of EB care or therapies for
non-EB-related SCCs were added during the iterative process
of guideline development from expert consensus.
© 2015 The Authors. British Journal of Dermatology
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Plans for updating the guidelines
It is anticipated that a literature search for new evidence per-
taining to the management of SCCs in EB will be undertaken
every 3 years after publication in order to update the guide-
lines. These revised guidelines will be hosted by the DEBRA
International website (http://www.debra-international.org/
homepage.html) to ensure their availability and dissemination
to clinicians and people living with EB.
Implementation of the guideline
As this guideline is intended for international use, it is not
possible to formulate a strategy for its implementation in all
clinical centres. However, the activities of DEBRA International
will aid in dissemination of the guidelines and facilitate adop-
tion by the proposed user groups.
Table 1 Summary of key recommendations
Strength of
recommendation
Quality of
evidence Key references
Surveillance and diagnosis
At-risk patients with EB should have regular
clinical surveillance for SCC
D III–IV 11–13
Areas of skin clinically suspicious for SCC should be
biopsied for histological evaluation
D III–IV 12,14,17,22
Tumour evaluation and staging
All patients with EB presenting with an SCC should
have multidisciplinary review
SCCs ≥ 5 cm diameter or overlying difficult anatomical
sites should be imaged with magnetic resonance imaging
or computed tomography to assess tumour extent
D III 15,16,27
Lymphadenopathy should be assessed for potential metastatic SCC D III 2,4,9,13,15–33
Patients with EB diagnosed with an SCC may require staging D III 4,13,20,22,24,27,34,35
Surgical treatment
Wide local excision is the treatment of choice for EB SCCs D III 2–6,8,9,13–16,18–22,24–27,30,32,33,36–60
Where an EB SCC excision is not possible, amputation of the
digit or limb may be needed
D III 3,9,10,13,14,17,18,20,22,23,25–27,29,30,34,
38,40,42,44,49,51,58,61–70
Regional lymph node dissection should be offered if nodal
SCC is identified by fine-needle aspiration or surgical biopsy
In some cases amputation may be favoured over wide
excision where it is believed that a more aggressive surgical
approach may reduce recurrence risk. Functional considerations
and patient preference should inform treatment decisions
The choice of wound closure may be guided by anatomical
considerations and availability of suitable donor skin or alternatives
Nonsurgical treatment
Radiotherapy may be a useful palliative modality for inoperable
EB SCCs or for subcutaneous, lymph node and distant metastases
D III 12–14,17,19,20,26,30,34,38,40,66,71,76
Radiotherapy may need to be delivered in smaller fractions to
minimize risk of severe skin desquamation in patients with EB
Conventional chemotherapy may be of some benefit used
palliatively in EB SCCs, but risks may outweigh benefits
EGFR antagonists and tyrosine kinase inhibitors may be useful
for palliation in advanced EB SCCs
Prosthetics
Limb prostheses may be used successfully in EB following
limb amputation
D III 61–63
End-of-life care
Appropriate analgesia should be prescribed to patients with EB
towards the end of life. A number of different routes of
administration of opioid analgesia may be used safely
C 1– 88–90
Psychological support of the patient with EB and family/carers is
vital after a diagnosis of SCC and as end-of-life care approaches
EB, epidermolysis bullosa; SCC, squamous cell carcinoma; EGFR, epidermal growth factor receptor.
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Surveillance and monitoring
SCCs may arise at a young age in patients with EB, particularly
those with RDEB-SG. This complication has been described in
a child as young as 6 years of age,2 and has been reported fre-
quently in patients aged < 20 years.3–10 As the incidence of
SCC increases with age in at-risk forms of EB, and patients fre-
quently develop multiple primary tumours,1 ongoing moni-
toring for patients with previous SCCs becomes even more
important (Table 1).
Clinical evaluation
SCCs may be difficult to identify clinically in patients with
EB because they frequently resemble areas of nonmalignant EB
ulceration and wounds. Indicators of SCC in patients with
EB include the following: (i) a nonhealing wound, lasting
longer than normal EB wounds (e.g. 4 weeks or more); (ii) a
rapidly growing wound, especially one that is heaped up,
resembling exuberant granulation tissue; (iii) a deep,
punched-out ulcer, especially if it has a raised or rolled edge;
(iv) an area of hyperkeratosis, especially if surrounded by a
shoulder of raised skin; and (v) a wound with altered sensa-
tion relative to normal EB wounds (e.g. tingling or increased
pain).
There should be a high index of suspicion for atypical
wounds. Regular skin checks should be performed in all at-
risk EB patient groups. (Strength of recommendation: good
practice point, GPP) (see Appendix 1).
D The risk of developing SCC in some subtypes of EB, and
the aggressive nature of these tumours, calls for vigilance and
clinical surveillance in these patients.11–13 (Strength of recom-
mendation D, quality of evidence III–IV.)
1 Patients with RDEB-SG have a very high risk of develop-
ing SCC and should have a full skin examination every
3–6 months from age 10 years. For other groups (domi-
nant dystrophic EB, generalized intermediate RDEB, RDEB
inversa, pretibial dystrophic EB, EB pruriginosa, general-
ized intermediate junctional EB and Kindler syndrome),
the risk of malignancy is not as high and it does not usu-
ally occur as early. Clinical screening for these lower-risk
groups should usually commence from age 20 years and
take place every 6–12 months, although if an SCC is diag-
nosed, 3-monthly screening should be undertaken subse-
quently.
2 Clinical screening should be undertaken by a dermatologist
and/or specialist nurse with experience of EB wounds,
where possible. All areas of a patient’s skin should be
examined and any relevant history about the duration and
symptoms from clinically suspicious wounds should be
sought. If it is not possible to examine all of the skin in
one sitting (due to constraints of dressing changes), the
skin should be examined serially over the course of a few
days to 1–2 weeks so that all areas are examined. Photog-
raphy of wounds at baseline for later comparison may be
helpful, especially when other eroded and crusted lesions
may arise in adjacent areas. Serial photography of suspi-
cious areas that will not undergo immediate sampling or
excision may be helpful, whenever possible and practical.
3 As they are responsible for day-to-day evaluation and
management of the skin, patients and families should be
educated about the risk of SCC and clinical features and
symptoms that might indicate malignancy. This is impera-
tive so that they are aware of the need to contact their
medical team as soon as possible if they have concerns.
4 Six-monthly dental review of at-risk patients with EB is
recommended so that the oral mucosae can be examined
and any areas of chronic ulceration or leucoplakia can be
biopsied. Patients should be advised to present sooner if
there are nonhealing areas.
5 Patients with a history of SCC should be clinically evaluated
at 3-monthly intervals. There is no evidence to advocate the
use of routine imaging for local or systemic spread, but clin-
ical examination (e.g. enlarged regional lymph nodes) or
symptoms (e.g. bony pain) may guide further investigations,
including fine-needle aspiration (FNA) of lymph nodes, flu-
orodeoxyglucose-positron emission tomography (FDG-PET)
scanning and computerized tomography (CT) scanning.
Biopsy of clinically suspicious lesions
D Areas of skin clinically suspicious for SCC should be biop-
sied for histological evaluation.14 (Strength of recommenda-
tion D, quality of evidence III–IV.)
1 Diagnostic biopsies (e.g. 3–4-mm punch biopsies) should
be taken from suspicious areas of skin for histopathologi-
cal examination. To minimize the risk of sampling error,
multiple biopsies around the edge of the lesion should be
taken. The position of each biopsy within the lesion
should be carefully recorded with clinical diagram(s) or
digital photograph(s).
2 Biopsies can generally be taken under local anaesthesia, but
occasionally they may need to be taken under general anaes-
thesia if multiple sites are to be sampled, especially in chil-
dren or anxious adults. Undertaking biopsies at the time of a
general anaesthetic for another procedure may be possible.
Alternatively, a regional nerve block or oral anxiolytic may be
utilized to minimize pain and anxiety when taking biopsies.
3 Reporting of biopsies from clinically suspicious EB
wounds should ideally be undertaken by a pathologist
experienced in examining EB biopsies, as there may be
difficulties in distinguishing SCC from granulation tissue
or pseudoepitheliomatous hyperplasia.
Tumour evaluation and staging
Once an SCC has been identified by diagnostic biopsies, fur-
ther evaluation may be necessary to stage the patient to make
the most appropriate management plan. Imaging of the pri-
mary tumour may guide surgical management, specifically the
feasibility of excision vs. the need for more radical surgery
© 2015 The Authors. British Journal of Dermatology
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such as amputation. Assessment of regional lymph node
involvement and possible distant metastatic spread may also
be required.
Evaluation of the primary tumour
All patients with EB presenting with an SCC should be dis-
cussed at a multidisciplinary meeting, where possible, with
relevant specialists: dermatologist, plastic surgeon, histopathol-
ogist and oncologist. This allows for review of the histology
and planning of staging and treatment. (Strength of recom-
mendation GPP.)
D Larger SCCs (≥ 5 cm in diameter) or those overlying
difficult anatomical sites should be imaged to assess their
extent, particularly whether they involve underlying structures
such as tendons, nerves and vessels.15,16 Magnetic resonance
imaging would be the investigation of choice, but where this
is not available, CT scanning may be undertaken. (Strength of
recommendation D, quality of evidence III.)
Evaluation of regional lymph nodes
D Patients with EB often have enlarged lymph nodes sec-
ondary to inflammation and colonization or infection of skin
wounds. However, it is important to assess lymphadenopa-
thy for potential metastatic SCC to plan treatment appropri-
ately. (Strength of recommendation D, quality of evidence
III.)
1 If regional lymph nodes are clinically palpable at the time
of presentation of the SCC, ultrasound-guided FNA (or,
in the case of inconclusive results at repeated FNA, surgi-
cal biopsy) should be undertaken to look for the presence
of SCC.4,13,17–25 If negative, no further evaluation is nec-
essary, although lymph nodes should be examined every
3 months and rebiopsied if there is evidence of further
enlargement. It should be noted that clinical evaluation
may be difficult if there is significant axillary scarring
making lymph node palpation difficult, in which case
ultrasound evaluation may be helpful.
2 If lymph node biopsy is positive for metastatic SCC,
regional lymph node dissection should be consid-
ered.2,9,13,15,19,21,25–30 This can usually be carried out at
the time of surgical excision of the primary SCC.
3 Sentinel lymph node biopsy (SLNB) may be undertaken in
patients with EB presenting with SCC.30 However, all
reports of SLNB in patients with EB have so far been nega-
tive for nodal SCC.20,31–33 As yet, there is no evidence that
SLNB results inform prognosis in EB SCCs, nor that under-
taking regional lymph node clearance in SLNB-positive
patients influences the eventual clinical outcome.
4 Regional lymph node clearance should be undertaken if
there is evidence of nodal disease on FNA or biopsy,
although there is no evidence that it affects prognosis.
However, removal of nodal SCC deposits may reduce sub-
sequent problems from ulceration and local complications
of secondary tumour deposits.
5 Regional lymph node dissection without proven nodal
SCC (elective nodal dissection) should not be undertaken
due to the morbidity associated with regional lym-
phoedema, which may exacerbate blistering, chronic
wounds and exudate levels in patients with EB.
Staging for distant metastases
D Patients with EB diagnosed with an SCC may require stag-
ing to determine the presence and extent of distant metastases,
as this will have a bearing on subsequent manage-
ment.4,13,20,22,24,27,34,35 (Strength of recommendation D,
quality of evidence III.)
1 Patients with a primary SCC ≥ 5 cm in maximum diame-
ter, or those with symptoms suggestive of metastatic
spread (e.g. localized bony pain, deranged liver function
tests, breathlessness), should undergo staging.
2 Where available, FDG-PET with CT scanning should be
undertaken. In interpreting the results, it should be noted
that in EB there may be nonspecific uptake of isotope on
PET scanning from chronic skin wounds, reactive lymph
nodes, the oesophagus and bone marrow, but combina-
tion with CT scanning can help to clarify the significance
of increased uptake.10,23,25,36,37
3 Where PET scanning is not available, a CT or magnetic res-
onance imaging scan of the chest, abdomen and pelvis
may identify systemic or lymph node metastases.
4 If CT scanning is unavailable, abdominal ultrasonography
and/or bone scanning may help to identify systemic
metastases.
Surgical treatment
Surgical excision is the standard treatment for EB SCCs,
although the techniques used may vary depending on the site
and size of the primary tumour. A number of approaches,
including wide local excision, Mohs micrographic surgery and
amputation are described, although evidence of the superiority
of one modality over another is lacking and, in practice, it may
be that one technique is preferred over another on anatomical
or functional grounds. Open discussion of surgical options with
the patient is paramount to ensure that the need for extensive
or potentially radical surgery is balanced with the patient’s
functionality and ability to carry out activities of daily living.
In addition to various techniques of tumour resection, a
number of different approaches to wound closure have also
been used for EB SCCs, including partial or full-thickness skin
grafting, the use of allografts or artificial skin equivalents, and
healing by secondary intention. However, there is no clear evi-
dence for the superiority of one modality over another, and the
choice may depend, therefore, on the size and anatomical loca-
tion of the wound, the availability of intact skin for autograft-
ing, and the availability of alternative graft materials.
If there is evidence of regional lymph node involvement,
block dissection should be undertaken, ideally at the same
© 2015 The Authors. British Journal of Dermatology
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time as excision of the primary tumour to minimize the num-
ber of anaesthetic procedures. Regional nodal disease or sub-
cutaneous metastases presenting after surgical excision of the
primary tumour may be amenable to surgical excision to pro-
vide palliative, symptomatic relief.
Wide local excision
D Wide local excision is considered the treatment of choice
for EB SCCs.2–6,8,9,13,15,18–22,24–27,30,32,33,36–60 However, if
imaging demonstrates involvement of underlying structures such
as vessels, nerves or tendons, this approach may not be possible
and more radical surgery (generally amputation) may be needed.
(Strength of recommendation D, quality of evidence III.)
Consideration should be given to the following.
1 Ideally there should be a 2-cm excision margin around
the tumour as assessed clinically. However, in practice it
may be difficult to define the extent of the tumour clini-
cally, and the margin may be limited by anatomical con-
siderations.
2 Marker sutures should be used so that the specimen can
be orientated for histopathological evaluation.
3 Ideally, the resection specimen should be mounted/
pinned to a board and photographed prior to sampling,
with clear labelling of blocks taken, allowing easy identi-
fication of the origin of subsequent slides. This facilitates
successful orientation of histological abnormalities. Dis-
cussion between the surgeon and histopathologist prior to
prosection also aids appropriate sampling and interpreta-
tion. Histopathological evaluation should determine
whether the lateral and deep margins of the wound are
clear of tumour, and if so state the distance of clearance.
If the margins are not clear, the report should state which
margin(s) is/are involved.
4 The histopathology report should comment on the thick-
ness and differentiation of the SCC (although in practice
all EB SCCs have the potential to behave aggressively inde-
pendently of histological grade) and whether vascular or
neural invasion is seen.
5 If there is evidence of residual tumour at a margin, re-ex-
cision of that portion of the wound should be considered.
Where anatomical or functional considerations mean that
this is not possible, amputation of an affected digit or
limb may need to be considered.
Amputation
D Where the size or anatomical location of an EB SCC means
that excision is not possible, it may be necessary to consider
amputation of the digit or limb.3,9,10,13,14,17,18,20,22,23,25–
27,29,30,34,38,40,42,44,49,51,58,61–70 (Strength of recommendation
D, quality of evidence III.)
Local recurrence of SCCs may render further local exci-
sion impossible and leave amputation as the treatment of choice.
In some cases amputation may be favoured over wide excision
where it is believed that a more aggressive surgical approach
may reduce the risk of recurrence; however, there is currently
no evidence to support this. Functional considerations should
also be borne in mind and discussed fully with the patient:
amputation with the prospect of using a prosthesis may be
preferable to wide excision leaving a painful wound and func-
tional impairment. (Strength of recommendation GPP.)
1 Amputation may be necessary if a tumour or recurrence
of a tumour is not amenable to wide local excision.
2 In some circumstances, amputation may be chosen in
preference to excision for functional reasons, particularly
if consideration is being given to subsequent use of a
prosthesis.
3 There is no evidence that amputation gives any survival
advantage over wide local excision.
4 Involvement of the patient in decisions about whether to
opt for amputation or not is vital; some may prefer to
avoid amputation to preserve function and independence,
even it if means that the SCC may cause more morbidity
and, perhaps, earlier mortality in the longer term.
Minimally invasive surgical techniques
A number of different techniques of minimally invasive sur-
gery have been used in EB SCCs, including Mohs micrographic
surgery, rush paraffin sections (‘slow Mohs’) and chemo-
surgery.13,14,35,62,66,71–75
There are some advantages of this approach: (i) examina-
tion of all of the excised tissue margin for histological evalua-
tion; (ii) confirmation of histological clearance in clinically
difficult-to-delineate EB SCCs and (iii) preservation of unin-
volved tissue (particularly when the location and size of the
tumour may compromise function and/or aesthetics).
However, a number of other factors should be considered.
Firstly, interpretation of frozen sections in EB SCCs may be
difficult; differentiating SCC from pseudoepitheliomatous
hyperplasia may be challenging, even for a histopathologist
experienced in these tumours. Secondly, EB skin is fragile so
excision by minimally invasive surgical techniques needs a
sharp surgical blade, a sharp cryostat blade and complete
freezing of the tissue prior to sectioning. Thirdly, if conven-
tional Mohs micrographic surgery with frozen sections is diffi-
cult, rush paraffin sections (‘slow Mohs’) may be used.
However, the extent of EB SCCs may mean that it is not feasi-
ble for the patient to have potentially large excision wounds
left unclosed pending results from each excision stage. Finally,
EB SCCs may be aggressive and have a high local, regional and
distant recurrence rate. It could be argued that getting a wider
excision margin is preferable to minimize the risks of
recurrence.
Despite the use of minimally invasive surgical tech-
niques in a number of EB SCCs, there is no evidence that
they are beneficial or detrimental in terms of further
management, morbidity or mortality. (Strength of recom-
mendation GPP.)
© 2015 The Authors. British Journal of Dermatology
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1 Minimally invasive surgical techniques may have a role
in the management of EB SCCs where the primary
tumour is difficult to define clinically, and therefore it is
difficult to be sure of excision margins at the time of
surgery.
2 Minimally invasive surgical techniques may have a role in
the management of EB SCCs where preservation of normal
tissue is imperative for functional or aesthetic reasons.
3 There is no evidence that the use of minimally invasive
surgery with clear margins for an EB SCC has any influ-
ence on the subsequent risk of recurrence.
Closure of surgical wounds
Different approaches to wound closure following excision of
EB SCCs have been employed, including healing by secondary
intention,13,24,34,35,60,75 autologous split skin,3–5,9,13–16,18–
22,24,33,39,41,43,44,48,49,53,55,57,59,73 epidermal39 or full-thick-
ness grafting,2,32,40,48,50,58 allogeneic skin grafting,28,38,58
cadaveric skin grafting,58 artificial skin equivalents,28,57,59
flaps,28,50,73–75 application of autologous or allogeneic ker-
atinocyte suspensions,27,28,59 or combinations of the
above.28,57 Of these techniques, split-skin grafting has been
most frequently employed, usually with meshing, although
donor sites in EB may be complicated by delayed healing.
Many different techniques of wound closure have been
used in EB SCC wounds. The choice of closure may be
guided by anatomical considerations and the availability of
suitable donor skin (for autografts), or the availability of
alternatives such as skin equivalents. (Strength of recommen-
dation GPP.)
There is insufficient evidence to indicate that any one
modality is associated with better healing than another,
although meshed split-skin grafts are the technique most com-
monly employed. (Strength of recommendation GPP.)
Autologous skin grafting may be complicated by
delayed healing of donor sites and may be inappropriate if
there are large or multiple sites requiring closure. (Strength of
recommendation GPP.)
Nonsurgical treatment
While surgery is the first-line treatment for the majority of
SCCs in EB, some clinical situations, notably when there has
been local recurrence of disease, or regional or distant metas-
tasis, may call for consideration of nonsurgical treatment such
as radiotherapy or chemotherapy. Topical modalities including
photodynamic therapy and 5-fluorouracil have also been used
in small numbers of patients, particularly for early, in situ
disease.
Radiotherapy
Radiotherapy has been used widely in the treatment of EB
SCCs, as either a definitive or palliative treatment of a primary
tumour13,14,20,26,34,38,40,76 or, more commonly, to palliate
local, regional or distant metastases, or following regional
lymph node dissection.12,17,19,30,66,71 Larger total radiation
doses appear to be associated with severe desquamation and
skin breakdown in patients with EB,66,71 although in other
cases radiotherapy has been well tolerated, particularly if
delivered in smaller fractions. Radiotherapy has also been used
as a primary treatment for mucosal SCCs in Kindler syndrome
and RDEB.76,77
Radiotherapy may be useful to reduce the primary
tumour size prior to surgical excision, but evidence that it is
effective as a definitive treatment is lacking. (Strength of rec-
ommendation GPP.)
D Radiotherapy may be a useful palliative modality for
locally recurrent EB SCCs as an alternative to surgical resection,
where surgery is not possible, or after regional lymph node
dissection. (Strength of recommendation D, quality of evi-
dence III.)
D Radiotherapy may be useful in palliation of subcuta-
neous, lymph node and distant (e.g. bony) metastases.
(Strength of recommendation D, quality of evidence III.)
Care should be given in planning radiotherapy in
patients with EB to minimize the risk of inducing severe
desquamation of overlying skin. The use of lower doses (e.g.
2 Gy) per fraction may help to minimize toxicity to the sur-
rounding or overlying skin. (Strength of recommendation
GPP.)
Conventional chemotherapy
There are only a few case reports describing the use of con-
ventional chemotherapy for palliation of advanced EB
SCCs.12,18,30,36,78,79 Agents used include cisplatin, carboplatin,
taxol, carboplatin, fluorouracil, doxorubicin and methotrexate.
Some reports describe partial remission, although this has usu-
ally been reserved for use in patients with very advanced dis-
ease, and there is little or no follow-up data available.
Concerns about septicaemia from indwelling vascular catheters
for delivering chemotherapeutic drugs, particularly when ther-
apy may cause neutropenia, should be taken into account
when considering conventional chemotherapy in EB SCCs.
D Conventional chemotherapy may be of some benefit
when used palliatively in EB SCCs, but the risk of septicaemia
due to indwelling vascular catheters and neutropenia may out-
weigh the potential benefits. (Strength of recommendation
GPP.)
Alternative biologic approaches
A raft of new biologic agents, notably epidermal growth factor
receptor (EGFR) antagonists and tyrosine kinase inhibitors,
have been used in non-EB SCCs.80–85 There are limited case
reports of favourable results with cetuximab (a monoclonal
antibody that binds the extracellular domain of EGFR) in
metastatic EB SCCs strongly expressing EGFR.30,36 The oral tyr-
osine kinase inhibitor erlotinib may be another putatively use-
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ful agent for advanced disease in this patient group. Both of
these classes of drug are associated with a frequent incidence
of acneiform rash and gastrointestinal disturbances.
EGFR antagonists and tyrosine kinase inhibitors may
prove useful palliatively in advanced EB SCCs, although at pre-
sent, evidence for their benefit is limited. (Strength of recom-
mendation GPP.)
Other nonsurgical techniques
A number of other nonsurgical modalities have been used in
EB SCCs, although most comprise single case reports with
scant information about response and outcome. These include
dermabrasion,14 cryotherapy,3 tubercidin, topical 5-fluo-
rouracil and injected purified protein derivative therapy,18 and
CO2 laser.
22 Photodynamic therapy with topical 5-aminolae-
vunlinic acid has been used successfully in a single case report
of Bowen disease on the finger in a patient with RDEB.86
Recently, favourable responses of EB SCCs to elec-
trochemotherapy have been published.87 Hyperthermic iso-
lated limb perfusion is a modality used in advanced
nonmelanoma cancers; although not reported in EB, this may
be a potentially useful therapy.88
Electrochemotherapy may be a potential treatment for
EB SCCs. (Strength of recommendation D, quality of evidence
III.)
Single case reports of other nonsurgical treatments for
EB SCC do not provide evidence that they are beneficial.
(Strength of recommendation GPP.)
PDT may be efficacious in Bowen disease in EB, although
the relative rarity of in situ disease relative to invasive SCC may
limit its application. (Strength of recommendation GPP.)
Prosthetics
Many patients with EB SCCs affecting limbs undergo amputa-
tion when the patient presents with advanced primary or
recurrent disease not suitable for wide local excision. Func-
tionally, the effect of losing part of a limb can be devastat-
ing, especially where function or mobility is already
compromised by scarring and contractures in other limbs.
Although the skin of an amputation stump in EB is fragile,
prostheses have been used with success, enabling patients to
transfer, ambulate and use their arms.61–63 Generally, using
lightweight prosthetic materials and soft padding (e.g. sili-
cone inserts or pads) will reduce trauma to the stump and
facilitate weight bearing.
D Limb prostheses may be used successfully in EB follow-
ing limb amputation, with appropriate care to minimize
trauma or friction to the stump. (Strength of recommendation
D, level of evidence III.)
Prevention
SCCs arising in EB occur early, are often multiple and have a
very poor prognosis. In addition, even early detection and
aggressive surgical excision do not appear to influence survival
outcomes, nor do they prevent further primary tumours from
developing. Experience in other conditions with a predisposi-
tion to cutaneous SCCs, such as xeroderma pigmentosum and
solid organ transplantation, has suggested benefit from use of
systemic retinoids to reduce the incidence of new tumours
arising.89,90 Other modalities, for example photodynamic ther-
apy or topical imiquimod, which might treat neoplastic
change early on before invasive SCC has developed, might also
be of benefit in EB. This is especially so where detection of
in situ SCC may be difficult on a background of scarred,
inflamed or eroded skin.
Systemic retinoids
There has been only one phase I clinical trial of systemic reti-
noids in patients with RDEB, in which isotretinoin was given
in doses of up to 05 mg kg1 per day for 8 months.31 This
was well tolerated, although some patients experienced
increased skin fragility on treatment. A single case report also
describes systemic etretinate (1 mg kg1 per day) in a patient
with large keratoacanthomas in generalized intermediate junc-
tional EB; there was no effect on the growth of the keratoa-
canthomas and therapy was stopped after 2 months due to
side-effects.43 Further work to explore whether systemic reti-
noids might be effective in chemoprevention of EB SCCs has
not been undertaken to date.
D Systemic retinoids may be well tolerated and safely
administered in EB.31 (Strength of recommendation D, quality
of evidence III.)
Although there have been no trials to explore whether
systemic retinoids are effective for primary or secondary chemo-
prevention of SCCs in EB, experience in other conditions in
which there is an increased risk of cutaneous SCC indicates that
there may be some benefit for patients with EB at high risk for
these tumours. (Strength of recommendation GPP.)
Other approaches
Photodynamic therapy with 5-aminolaevulinic acid has been
used to treat Bowen disease in a single patient with RDEB,86
and may be a modality that could be used to target subclinical
foci of in situ disease in EB before the development of invasive
SCC. Similarly, other topical measures such as 5-fluorouracil
or imiquimod may be potential treatments for early disease.
However, at present there is no evidence to support their use.
End-of-life care
Due to the very aggressive nature of SCCs in EB, many
patients with these tumours reach the point at which their
disease is no longer ‘curative’, and efforts must be directed
towards palliation and providing the best quality of life for
that individual. Ideally, management should take place within
a multidisciplinary team of health professionals including a
dermatologist, specialist nurse, surgeon, oncologist, psycholo-
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gist and pain or palliative care specialist. However, central to
any holistic decision-making processes are the patient them-
selves and their family/carers. There may be situations in
which the patient opts not to have particular treatments,
even when the medical advice they are receiving suggests
that it could be to their benefit. Making sure that the patient
is informed of all possible options, the pros and cons of
each, and supporting them in their decision as to which (if
any) they would like to pursue is paramount. The patient’s
and family’s wishes should also be listened to in making
decisions about, for example, where they wish to die, and
feeding and hydration.91
Pain management
Patients with EB with advanced SCCs may experience pain
from their primary tumour, locoregional spread or distant
metastases. Towards the end of life, efforts should focus on
alleviating this pain,92 without the usual concerns of toler-
ance of or addiction to opioid analgesics, although it is
important to be mindful that using larger doses of opioids
may make the patient less alert and responsive. Opioids may
be given by a variety of routes to cover background, acute or
procedural pain. Topical morphine in a hydrogel can be
applied directly to a painful malignant wound and replaced at
each dressing change.93,94 Subcutaneous opioids can be deliv-
ered by a syringe driver with the cannula held in place with
soft silicone tape to facilitate removal.94,95 Opioid patches
may also be helpful in delivering sustained-release analgesia,
and can be taken off atraumatically with a medical adhesive-
removal spray.94,95 Radiotherapy may be used to alleviate
pain from bony metastases.
C Appropriate analgesia should be prescribed to alleviate
pain in patients with EB with SCC towards the end of life. A
number of different routes of administration of opioid analge-
sia may be used safely in patients with EB, including topical
morphine gel. (Strength of recommendation C, quality of evi-
dence 1.)
Wound management
Malignant EB wounds are often complicated by significant
exudate and odour.94,95 Low-air-loss mattresses can help to
redistribute pressure to aid patient comfort and help deal with
high volumes of exudate. A number of dressings are also spe-
cially designed to absorb and hold exudate away from the skin
to minimize maceration of surrounding tissues. Charcoal,
honey or silver dressings may reduce odour, and deodorizers
may be helpful to mask it.94 When EB SCCs or metastases
overlie blood vessels, especially larger arteries and veins, such
as in the groins or axillae, there is a risk of tumour invasion
and catastrophic bleeding. In these situations, it may be possi-
ble to ensure that there are dark-coloured towels at hand to
absorb and cover the blood loss, and to administer a fast-
acting benzodiazepine such as midazolam subcutaneously or
buccally to reduce patient anxiety.94
A variety of dressings designed to cope with wounds that
have high exudate levels or odour may be helpful in managing
EB SCC wounds. (Strength of recommendation GPP.)
Where an EB SCC or metastasis overlies blood vessels,
consideration should be made of the risk of potentially catas-
trophic bleeding and how to alleviate anxiety in the patient and
family should this happen. (Strength of recommendation GPP.)
Psychological support
Psychological support of a patient with EB should ideally be
part of holistic, multidisciplinary care throughout life,
although following the diagnosis of SCC the psychological
needs of the patient and their family/carers may increase
greatly. Towards the end of life, this is particularly important
to help the patient and family adjust to the situation and to
help communicate concerns and wishes. Following death,
ongoing bereavement support of the family should be offered.
Psychological support of the patient with EB and fam-
ily/carers is important throughout life, but particularly vital
after a diagnosis of SCC and as end-of-life care approaches.
(Strength of recommendation GPP.)
Support following bereavement may also be welcome
for the family/carers. (Strength of recommendation GPP.)
Additional measures
During end-of-life care, patients with EB may be in great dis-
comfort when moved for dressing changes or for personal care.
In some situations, it may be reasonable to insert a small soft
silicone urinary catheter to reduce the need for toileting and to
reduce soiling of dressings.94,95 Whereas catheterization is gen-
erally avoided in EB when not essential, due to the risk of ure-
thral stricturing, in the context of being close to dying this is
not a consideration. Where oral intake has reduced signifi-
cantly, patients may be thirsty. It is reasonable to consider giv-
ing nasogastric or subcutaneous fluids (with the nasogastric
tube cannula secured with soft silicone tape), so long as this
does not cause undue distress to the patient. In patients with
EB who are close to death, the benefits of undertaking dressing
changes (comfort, and exudate and odour control) should be
weighed against the discomfort that the dressings may entail.
Ideally, the patient and/or family/carers should be involved in
deciding how and when to carry out dressing changes.
Urinary catheterization and giving nasogastric or subcu-
taneous fluids towards the end of life in EB may be beneficial
in some cases if they outweigh discomfort. Similarly, patients
may be more comfortable having less frequent dressings or
even forgoing dressing changes completely at this stage. The
patient and family/carers should be central to this decision
making. (Strength of recommendation GPP.)
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Appendix 1
Levels of evidence
1++ High-quality meta-analyses, systematic reviews of
RCTs or RCTs with a very low risk of bias
1+ Well-conducted meta-analyses, systematic reviews or
RCTs with a low risk of bias
1 Meta-analyses, systematic reviews or RCTs with a high
risk of bias
2++ High-quality systematic reviews of case–control or
cohort studies
High-quality case–control or cohort studies with a very
low risk of confounding or bias and a high probability
that the relationship is causal
2+ Well-conducted case–control or cohort studies with a
low risk of confounding or bias and a moderate probability
that the relationship is causal
2 Case–control or cohort studies with a high risk of
confounding or bias and a significant risk that the
relationship is not causal
3 Nonanalytical studies, e.g. case reports, case series
4 Expert opinion
RCT, randomized controlled trial.
Grades of recommendation
A At least one meta-analysis, systematic review or RCT rated
as 1++, directly applicable to the target population; or
A body of evidence consisting principally of studies rated
as 1+, directly applicable to the target population, and
demonstrating overall consistency of results
B A body of evidence including studies rated as 2++, directly
applicable to the target population, and demonstrating overall
consistency of results; or
Extrapolated evidence from studies rated as 1++ or 1+
C A body of evidence including studies rated as 2+, directly
applicable to the target population and demonstrating overall
consistency of results; or
Extrapolated evidence from studies rated as 2++
D Evidence level 3 or 4; or
Extrapolated evidence from studies rated as 2+
RCT, randomized controlled trial. The grade of recommendation
relates to the strength of the evidence on which the recommen-
dation is based. It does not reflect the clinical importance of the
recommendation.
Good practice points
Recommended best practice based on the clinical experience
of the guideline development group
Adapted from the SIGN 50 Guideline Developer’s Handbook, NHS Scot-
tish Intercollegiate Guidelines Network, revised edition January
2014.
© 2015 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2015)
12 Best practice guidelines for EB-associated cutaneous SCCs, J.E. Mellerio et al.
